In the last trading session, 1.19 million shares of the Twist Bioscience Corp (NASDAQ:TWST) were traded, and its beta was 1.62. Most recently the company’s share price was $34.31, and it changed around -$0.17 or -0.49% from the last close, which brings the market valuation of the company to $1.98B. TWST currently trades at a discount to its 52-week high of $43.21, offering almost -25.94% off that amount. The share price’s 52-week low was $11.46, which indicates that the current value has risen by an impressive 66.6% since then. We note from Twist Bioscience Corp’s average daily trading volume that its 10-day average is 0.68 million shares, with the 3-month average coming to 944.68K.
Twist Bioscience Corp stock received a consensus recommendation rating of Buy, based on a mean score of 1.89. If we narrow it down even further, the data shows that 0 out of 3 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 1 recommended TWST as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Twist Bioscience Corp is expected to report earnings per share of -$0.81 for the current quarter.
Twist Bioscience Corp (NASDAQ:TWST) trade information
Instantly TWST has showed a red trend with a performance of -0.49% at the end of last trading. The performance over the last five days has remained in the red territory. The company’s shares are currently down -6.92% year-to-date, but still down -4.77% over the last five days. On the other hand, Twist Bioscience Corp (NASDAQ:TWST) is -14.76% down in the 30-day period. We can see from the shorts that 12.01 million shares have been sold at a short interest cover period of 14.44 day(s).
The consensus price target as assigned by Wall Street analysts is $37.67, which translates to bulls needing to increase their stock price by 8.92% from its current value. Analyst projections state that TWST is forecast to be at a low of $32 and a high of $45.
Twist Bioscience Corp (TWST) estimates and forecasts
Twist Bioscience Corp share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 67.04 percent over the past six months and at a 12.43% annual growth rate that is well below the industry average of 13.00%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 22.10% in revenue this quarter, and will report an increase of 23.80% in the next quarter. The year-over-year growth rate is expected to be 19.60%, up from the previous year.
Consensus estimates provided by 8 financial analysts predict the company will bring in an average of $70.65 million in revenue for the current quarter. 8 analysts expect Twist Bioscience Corp to make $73.8 million in revenue for the quarter ending Jun 2024.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -6.09%.
TWST Dividends
Twist Bioscience Corp’s next quarterly earnings report is expected to be released around May 03 and May 07.
Twist Bioscience Corp (NASDAQ:TWST)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.79% of Twist Bioscience Corp shares, and 113.08% of them are in the hands of institutional investors. The stock currently has a share float of 115.14%. Twist Bioscience Corp stock is held by 331 institutions, with Blackrock Inc. being the largest institutional investor. By Jun 29, 2023, it held 12.03% of the shares, which is about 6.91 million shares worth $141.28 million.
ARK Investment Management, LLC, with 11.82% or 6.79 million shares worth $137.48 million as of Sep 29, 2023, holds the second largest percentage of outstanding shares.
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and ARK ETF Tr-ARK Innovation ETF were the top two Mutual Funds as of Aug 30, 2023. The former held 3.49 million shares worth $76.77 million, making up 6.08% of all outstanding shares. On the other hand, ARK ETF Tr-ARK Innovation ETF held roughly 3.48 million shares worth around $70.48 million, which represents about 6.06% of the total shares outstanding.
